Kira Biotech develops novel immunomodulatory drugs targeting immune system disorders, utilizing advanced therapeutic antibody technologies to enhance treatment efficacy. The company focuses on addressing unmet medical needs in immunology, particularly for conditions such as rheumatoid arthritis and other immune-mediated diseases.
Funding
$13.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
OFounders
Product
Problem
Many immune system disorders lack targeted and effective treatments, leading to chronic inflammation, tissue damage, and reduced quality of life for patients. Current therapies often have broad immunosuppressive effects, increasing the risk of infection and other adverse events. There is a need for novel drugs that can selectively modulate the immune system to restore balance and resolve disease.
Solution
Kira Biotech is developing a pipeline of immunomodulatory drugs based on therapeutic antibody technologies to address unmet needs in immunology. Their approach focuses on precisely targeting key immune pathways involved in the pathogenesis of autoimmune and inflammatory diseases. By selectively modulating the immune response, Kira Biotech aims to develop therapies that are both more effective and safer than existing treatments. These novel antibodies are designed to enhance treatment efficacy while minimizing off-target effects and improving patient outcomes in conditions such as rheumatoid arthritis and other immune-mediated diseases.
Target Audience
The primary target audience includes patients suffering from immune system disorders such as rheumatoid arthritis and other immune-mediated diseases, as well as the physicians who treat them.
Features
- Development of novel therapeutic antibodies targeting specific immune pathways
- Focus on immunomodulation to restore immune system balance
- Addressing unmet medical needs in autoimmune and inflammatory diseases
- Potential for enhanced treatment efficacy and improved safety profiles